The committee will consider the impact of changes made by NICE to
evaluate drugs used to treat patients with terminal illness like
cancer in this session.
The Future Cancer inquiry
received evidence from drugs' companies that changes by NICE in
2022 on the cost-effectiveness of drugs for severe diseases do
not sufficiently weight treatments used in advanced cancer. They
say that as a result some cancer patients may miss out on last
resort treatments.
MPs will also consider the breast cancer drug Enhertu which in
draft guidance from NICE has not been recommended for treating
secondary breast cancer in England.
The APPG on Breast Cancer will hold a roundtable event focusing
on this issue later the same day.
Witnesses
Wednesday 8 May in Committee Room 8, Palace of Westminster
At 9.30am
- David Brocklehurst, Head of Oncology at AstraZeneca UK
- Haran Maheson, Vice President and Head of Oncology at Daiichi
Sankyo UK
At 10.15am
- Baroness Delyth Morgan, Chief Executive at Breast Cancer Now
At 10.45am
- Helen Knight, Director of Medicines Evaluation, National
Institute for Health and Care Excellence (NICE)
- Dr Sam Roberts, Chief Executive, National Institute for
Health and Care Excellence (NICE)
Future cancer
- The Future cancer inquiry has completed
taking evidence and will publish its report in due course. The
inquiry builds on the Committee's earlier work and report on Cancer
services (April 2022) which found the government was not on
track to meet the 75% early diagnosis target by 2028, set out
in the NHS Long Term Plan.
- An evaluation by the
Committee's independent Expert Panel on Government commitments
relating to cancer rated overall progress as “inadequate”.
